Table 1 Pooled population demographics and baseline characteristics
Characteristic | Revefenacin 175 μg (n = 395) | Placebo (n = 417) |
|---|---|---|
Sex, male, n (%) | 195 (49.4) | 206 (49.4) |
> 65 years, n (%) | 176 (44.6) | 185 (44.4) |
> 75 years, n (%) | 35 (8.9) | 42 (10.1) |
Current smoker, n (%) | 190 (48.1) | 198 (47.5) |
Concurrent LABA or ICS/LABA, n (%) | 153 (38.7) | 147 (35.3) |
Concurrent ICS, n (%) | 174 (44.1) | 171 (41.0) |
FEV1 30%–< 50% pred, n (%) | 119 (30.1) | 134 (32.1) |
FEV1 < 30% pred, n (%) | 26 (6.6) | 16 (3.8) |
2011 GOLD category D, n (%) | 132 (33.4) | 141 (33.8) |
Reversible to ipratropium and albuterol, n (%) | 86 (21.8) | 82 (19.7) |
History of cardiovascular diseasea | 178 (45.1) | 200 (48.0) |
History of diabetes | 80 (20.3) | 78 (18.7) |
History of cognitive/mental impairments | 58 (14.7) | 61 (14.6) |